A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness

Petra Behnen, Angelo Felline, Antonella Comitato, ..., Krzysztof Palczewski, Valeria Marigo, Francesca Fanelli

valeria.marigo@unimore.it (V.M.)
fanelli@unimo.it (F.F.)

HIGHLIGHTS

In silico and in vitro analyses of adRP rhodopsin mutants bridged folding and routing

Structure network analysis grouped mutants amenable to treatment with small chaperones

Virtual compound screening against the stability core of opsin found a small chaperone

The pharmacoperone is a reversible orthosteric inhibitor of retinal binding

Behnen et al., iScience 4, 1–19 June 29, 2018 © 2018 The Authors.
https://doi.org/10.1016/j.isci.2018.05.001
A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness

Petra Behnen,1,6 Angelo Felline,2,6 Antonella Comitato,1 Maria Teresa Di Salvo,1 Francesco Raimondi,2,7 Sahil Gulati,3,4 Shirin Kahremany,1 Krzysztof Palczewski,3,4 Valeria Marigo,1,5,* and Francesca Fanelli2,5,8,*

SUMMARY

The autosomal dominant form of retinitis pigmentosa (adRP) is a blindness-causing conformational disease largely linked to mutations of rhodopsin. Molecular simulations coupled to the graph-based protein structure network (PSN) analysis and in vitro experiments were conducted to determine the effects of 33 adRP rhodopsin mutations on the structure and routing of the opsin protein. The integration of atomic and subcellular levels of analysis was accomplished by the linear correlation between indices of mutational impairment in structure network and in routing. The graph-based index of structural perturbation served also to divide the mutants in four clusters, consistent with their differences in subcellular localization and responses to 9-cis retinal. The stability core of opsin inferred from PSN analysis was targeted by virtual screening of over 300,000 anionic compounds leading to the discovery of a reversible orthosteric inhibitor of retinal binding more effective than retinal in improving routing of three adRP mutants.

INTRODUCTION

Conformational and misassembly diseases are disorders of protein folding, often due to missense mutations, which compromise protein function (Sanders and Myers, 2004; Lin and Liu, 2006; Conn and Ulloa-Aguirre, 2010). Potential pharmacological therapies for these diseases are based on promoting correct folding, inhibiting aggregation, increasing degradation, or protection from cell death (Mendes and Cheetham, 2008; Mendes et al., 2005). Many diseases associated with misfolding and ER retention involve membrane proteins, including G protein-coupled receptors (GPCRs) like rhodopsin (RHO) (Conn and Ulloa-Aguirre, 2010; Sanders and Myers, 2004; Castro-Fernandez et al., 2005; Gregersen et al., 2006; Gregersen, 2006; Mendes et al., 2005).

Most of the over 140 missense mutations found in RHO are linked to the autosomal dominant form of retinitis pigmentosa (adRP) (Briscoe et al., 2004). Retinitis pigmentosa comprises a group of hereditary human diseases that are the most common cause of inherited blindness in developed countries (Kennan et al., 2005; Mendes et al., 2005). The majority of adRP RHO mutants have been the subject of extensive biochemical and cellular characterizations in heterologous expression systems and transgenic animals, leading to a classification into three major groups (I, Ila/II, and IIb/III) (reviewed in Briscoe et al., 2004; Krebs et al., 2010).

Class I mutants resemble wild-type (WT) in yield, electrophoretic pattern, ability to regenerate with 11-cis retinal, and subcellular localization. In contrast, class Ila (or II in Krebs et al., 2010) and class IIb (or III in Krebs et al., 2010) mutants show altered membrane localization when expressed in cell culture in the absence of retinal and compromised or uncompromised abilities, respectively, to regenerate with retinal in vitro (Table S1). Another classification of RHO mutants linked to adRP and autosomal dominant congenital stationary night blindness (adCSNB) accounted not only for ER retention and impairment in retinal binding (class 2) but also for effects on other aspects of RHO function, such as post Golgi trafficking and outer segment targeting (class 1), vesicular trafficking and endocytosis (class 3), post-translational modifications (class 4), transducin activation (class 5), constitutive activity (class 6), and dimerization efficiency (class 7) (Mendes et al., 2005; Athanasiou et al., 2018) (Table S1).

Almost 90% of the biochemically characterized adRP RHO mutants are likely to be misfolded (reviewed in Briscoe et al., 2004; Krebs et al., 2010; Rakoczy et al., 2011; Athanasiou et al., 2018), supporting a protein-misfolding disease model suitable for treatment with pharmacological chaperones, i.e., small molecules...
that bind specific sites within a protein’s native or quasi-native structure, thereby shifting the folding equilibrium toward the native state.

RHO is the visual pigment of rod photoreceptor cells that activates the phototransduction cascade following light capture (Palczewski, 2006). It is composed of a protein opsin (OPS) and a chromophore, 11-cis retinal, forming a protonated Schiff base (PSB) with the amino acid residue K296 (Figure 1A) (Palczewski, 2006). Opsins are densely packed into specific regions of the cell, the membranous discs of the rod outer segment (ROS), which prevents their random diffusion and allows efficient absorption of light (Palczewski, 2006; Kiser et al., 2014; Sakami et al., 2014; Fotiadis et al., 2003; Gunkel et al., 2015). Upon photon absorption that causes the cis-trans isomerization of 11-cis retinal, RHO ultimately reaches the metarhodopsin II (MII) state able to activate the heterotrimeric G protein transducin (Gt), thus triggering the visual phototransduction cascade (Hofmann et al., 2009).

RHO is the GPCR best characterized at atomic resolution in its inactive and active states. To date, high-resolution structures have been obtained for the dark state (Li et al., 2004; Palczewski et al., 2000), a number of photo-intermediates (reviewed in Palczewski, 2006; Fanelli and De Benedetti, 2011), an active form of the OPS apoprotein (Park et al., 2008), and the MII state (Choe et al., 2011).

The quantity of high-resolution information about the different RHO states makes this protein especially suitable for deciphering the structural determinants of conformational diseases linked to GPCR mutations. Indeed, understanding the molecular bases of such diseases requires the characterization of the interacting forces that found the native state and that, if impaired, lead to misfolding. Advances in that respect was made by our previous computational experiments that highlighted a number of adRP mutations as likely impairing the structural stability of the second extracellular loop (EL2) (Felline et al., 2009) and a number of highly connected amino acids in proximity to the retinal-binding site and the G protein-binding regions (Fanelli and Seeber, 2010). The latter study relied on the combination of mechanical unfolding simulations and protein structure network (PSN) analysis, a cutting-edge approach to unravel different aspects of protein function, including folding and stability (Vishveshwara et al., 2009; Fanelli et al., 2013).
In the present study, by integrating PSN analysis of novel molecular simulations with in vitro experiments, we determined the effects of 33 different adRP mutations on the native structure network and on the subcellular localization of both the RHO and OPS states. The putative stability core of the protein inferred from the PSN analysis was targeted by virtual screening of compounds leading to the discovery of a potential therapeutic agent as a pharmacological chaperone able to mitigate ER retention and restore plasma membrane localization of three adRP mutants.

RESULTS
Local Perturbation at Mutation Sites
Molecular dynamics (MD) simulations of 33 adRP mutants in their apo and 11-cis retinal-bound states (Figure 1A, Table S2) were compared with those of the native RHO and OPS states. References on the discovery and biochemical characterization of the mutants under study are provided in Briscoe et al., 2004; Krebs et al., 2010; Rakoczy et al., 2011; Athanasiou et al., 2018.

Local perturbations induced by mutations displayed a variety of profiles (Table S2). Briefly, the N-terminus mutation sites are located in structured portions (i.e., a β-hairpin for T4 and two different types of turns for T17, P23, and Q28) and the mutations affect backbone conformation in addition to local side chain packing interactions, which may contribute to variations in N-linked glycosylation as observed for the mutants at T4, T17, and P23 (Tam and Moritz, 2009; Chen et al., 2014; Sakami et al., 2011). Effects on backbone conformation also arise from mutations of glycine, proline, and threonine in the helices (H) or in EL2.

Mutations in arginine often generate non-native salt bridges involving E25 or, more frequently, E122 or E181 (shadowed in Table S2). The only case of arginine replacement, the R135W mutant, is characterized by loss of the native salt bridges between R135 and both E134 and E247 and establishment of van der Waals interactions between W135 and hydrophobic amino acids in H6 (shadowed in Table S2). It is worth noting that R135 is the highly conserved arginine of the E/DRY motif, an amino acid residue playing a central role in G protein recognition as shown by X-ray crystallographic determinations (Scheerer et al., 2008; Rasmussen et al., 2011). The R135W mutant was found to be hyperphosphorylated and bound with high affinity to the visual protein arrestin (Chuang et al., 2004).

As for the three mutants characterized by an aspartate substitution (i.e. V87D, G89D, and G114D), the establishment of a non-native salt bridge concerns only D114 that, in the RHO form, acts as a counterion of the PSB (shadowed in Table S2). Other perturbations may result in either breakage of native disulfide bridges (C187Y), or formation of non-native disulfide bridges (Y178C), or both (C110Y) (shadowed in Table S2).

Structure Network-Based Characterization and Clustering of adRP Mutants
To determine similarities and differences between adRP mutants likely related to function despite the high heterogeneity of the local perturbations at the mutation site, our study focused on the long-range propagation of mutational effects. These were investigated by PSN analysis, which is based on the application of graph theory to protein structures (Brinda and Vishveshwara, 2005; Fanelli et al., 2013). In a protein structure graph (PSG), each amino acid is represented as a node and nodes are linked together based upon the strength of their non-covalent interaction. Hyperlinked nodes are defined as hubs, and they are likely to play a central role in protein stability. MD simulations of native OPS and RHO both at 300 K and at melting conditions (i.e., 329 K for OPS and 345 K for RHO [Khan et al., 1991]) served to identify the most stable (i.e., most persistent) structure network elements characterizing the native states.

To compute the native stable structure network, the frequencies of all hubs and links in the 300 K network were averaged with the frequencies of the same hubs and links in the corresponding melting temperature network (see Methods). Hubs and links holding an average frequency ≥ 50% were defined as stable and included in the native network. Native stable hubs in RHO tend to occur in EL2 as well as in all helices except for H1 and H4 (Figure 1B). EL2, H3, and H6 are particularly enriched in hubs, which include highly conserved amino acids (R135, F261, W265, Y268, and Y306 [Mirzadegan et al., 2003]) as well as amino acids involved in inter-helical interactions or in retinal binding (N78, E113, E122, W126, F203, H211, W265, Y268, and K296) (Table S3). A significant part of these hubs (M44, T94, R135, P180, Q184, D190, H211, and K296) are sites of pathogenic mutations (Briscoe et al., 2004). The chromophore is one of the most recurrent hubs (average frequency, 91%). The absence of this hub in OPS results in a significant rearrangement of the structure network (Figure 1C). Changes concern the loss of six stable hubs (from 23 to 17, Table S3) and 12 stable
links (from 194 to 182, Table S3) in OPS compared with RHO, which correlates with the lower melting temperature of the former (Khan et al., 1991). While 76% of the native OPS stable hubs are retained in the RHO state, native stable links undergo a more significant rearrangement following the addition of 11-cis retinal. In fact, OPS and RHO share 106 stable links, whereas the number of links specific to one of the two forms is 76 for OPS and 88 for RHO (Table S3).

On this basis we used such network elements to describe and quantify likely structural differences between each mutant and the two native states generated by the absence or presence of retinal. The differences in structure networks between WT and mutants were effectively quantified using the following computational index, network perturbation (NP):

$$\text{Mut}_{\text{NP}} = 100 \left( \frac{\sum_{i=1}^{\text{WT hubs tot}} \left( \frac{\text{WT hubs} - \text{Mut hubs}}{\text{WT hubs}} \right), \text{ if WP hubs tot} > \text{Mut hubs tot}}{0, \text{ otherwise}} \right)$$

where $\text{Mut}_{\text{miss}}$ is the number of missing native stable links in the mutant network and $\text{WT hubs tot}$ is the total number of native stable links. $\text{WT hubs tot}$ is the total number of native stable hubs and $\text{Mut hubs}$ and $\text{WT hubs}$ are the frequencies of native stable hubs $i$ in the mutant and WT networks, respectively. The higher the score, the greater the loss in native stable hubs and native stable links associated with a given mutant. The NP score accounts for mutation-induced perturbations in the structure network describing the native states of OPS and RHO.

The NP indices computed for OPS and RHO for each mutant (Figures 2A and 2B, respectively), and the differences between them ($\Delta \text{NP}$, Figure 2C) were used to cluster the mutants (see Methods for details on clustering), leading to four groups (Figure 2 and Table S4). Cluster 1 (white in Figures 2A–2C) groups the mutants characterized by low NP in both OPS and RHO, as well as low $\Delta \text{NP}$; cluster 2 (blue in Figures 2A–2C) groups the mutants characterized by high and low NP in OPS and RHO, respectively, as well as high $\Delta \text{NP}$; cluster 4 (black in Figures 2A–2C) groups the mutants characterized by high NP in both OPS and RHO as well as low $\Delta \text{NP}$. Finally, for the members of cluster 3, the NP values are high in OPS, whereas they tend to hold values between those of clusters 2 and 4 in RHO, resulting as well in intermediate $\Delta \text{NP}$ scores (gray in Figures 2A–2C). On average, clusters 1 and 4 show, respectively, the lowest and highest destabilization of the native structure network independent of the presence of 11-cis retinal, whereas cluster 2 resembles cluster 4 in the absence of 11-cis retinal and cluster 1 in the presence of 11-cis retinal (Figure 2D). In other words, for cluster 2 the presence of 11-cis retinal hinders structural impairments by the mutations.

In addition, a linear trend was observed between the NP index and a spectroscopic index from the literature that accounts for the degree of misfolding of RHO mutants as compared with WT (Figure S1) (Kaushal and Khorana, 1994; Hwa et al., 1997, 1999; Iannaccone et al., 2006; Andres et al., 2003; Stojanovic et al., 2003; Bhattacharya et al., 1992). This trend is consistent for eleven of the sixteen mutants for which the spectroscopic index could be determined. The spectroscopic index, which is the ratio between the absorbances at 280 nm (due to tryptophan and aromatic residues in the protein) and at 500 nm (reflecting 11-cis retinal binding), reflects the ratio between misfolded and folded (retinal-bound) protein. Since spectroscopic determinations of the different mutants were not made by the same laboratory, we divided the absorbance ratio ($A_{280}/A_{500}$) of a given mutant by that of the WT to normalize the indices. The WT index from the different laboratories ranged from 1.6 to 2 (Table S5). For the mutants C110Y, G114D, C167R, P171Q, Y178C, E181K, S186P, C187Y, D190Y, H211P, C222R, and P267L, some laboratories reported no detectable absorbance at 500 nm, indicating the absence of retinal binding (Andres et al., 2003; Hwa et al., 1997, 1999; Kaushal and Khorana, 1994). This agrees with the observation that most of those mutants fall in clusters 3 and 4 assigned in this study. Consistently, most mutants, for which the $A_{280}/A_{500}$ index could be determined, fall in cluster 1. Together these data suggest that the NP score is somehow related to a commonly used index of RHO misfolding.

The selected NP is almost always the center of the three closest values obtained from different MD trajectories. The use of the NP index relative to a single MD trajectory (at the two different temperatures) instead
of an average value served to favor structural interpretability, while keeping the main inferences from the analysis. Indeed, the results of cluster analysis do not change if they are based on the average NP values (Figure S2).

In summary, we defined a structure graph-based index describing the perturbations induced by adRP mutations on the native structure network of the OPS and RHO states. This index also served to divide the mutants into four clusters accounting for the different structural responses to retinal, which is maximal for the members of cluster 2.

**Structural Signatures of the Four Clusters of adRP Mutants**

The members of each cluster tend to share a common behavior in terms of 11-cis retinal deformation. The latter is described by the retinal outer van der Waals volume (i.e., the size/shape descriptor Vout, see Methods [De Benedetti and Fanelli, 2010; Fanelli and De Benedetti, 2011]) in a given mutant relative to the retinal volume in WT RHO (Figure 2E). The higher the value of Vout, the greater the degree of retinal deformation. As shown in Figure 2E and Table S4, cluster 1 and 2 mutants on average tend to show the lowest Vout values, whereas cluster 4 mutants show the highest value.
Signatures of each cluster, as inferred from the structure networks, are the native stable links that undergo an average frequency reduction in the mutant trajectories participating in the cluster (Figures 3 and Table S6). As for the extracellular half of the receptor where the retinal-binding site is located, in the OPS state cluster 1 displays the lowest perturbation of native stable links compared with the other three clusters in terms of reduction in number and frequency (Figure 3A). Remarkably, the presence of 11-cis retinal prevents major perturbations shared in OPS by the members of cluster 1 and, more prominently, of cluster 2 (Figures 3A–3D), whereas the chromophore is less effective for clusters 3 and 4 (Figures 3E–3H).

In the RHO state the members of cluster 4 share link weakening that spans the retinal-binding site to the extreme N-terminus (Figures 3G and 3H) and involves (1) the links between E113 and both retinal and K296; (2) the links between M288 and Y268, V271, and I275; (3) the links in the amino acid pairs F9-F24, Q36-A32, T94-F293, S98-C185, C264-T297, and W265-A295; (4) the links between F283 and both I275 and F287; and (5) the network involving P12, N200, V204, and the amino acid stretch 189–194 (Table S6).

Figure 3. Native Stable Links Weakened by Mutation
(A–H) Native stable links undergoing an average reduction in frequency ≥ 25% within each cluster are shown on the crystal structures of OPS (A, C, E, and G) and RHO (B, D, F, and H). Nodes and links are colored according to their average frequency reduction. Cyan, dark cyan, blue, and dark blue represent average reductions up to 30%, 40%, 50%, and greater than 50%, respectively. See also Table S6.
As for the intracellular half of OPS, all clusters share reduction in frequency for several native links that involve highly conserved amino acids and/or adRP mutation sites. These residues include N55 in H1, L125 and the glutamate and arginine pair of the ERY motif in H3, Y223 in H5, F261 in H6, the NPxxY motif in H7, and F313 in H8 (Figure 3 and Table S6). In contrast, in RHO all clusters share limited perturbation of the native stable links in the intracellular half, likely related to a long-range effect of retinal, which is greatest for the mutants in clusters 1 and 2 (Figure 3).

Collectively, all clusters show marked link destabilization in OPS as an effect of mutation on backbone and side-chain structure and dynamics. Major structural differences among the four clusters reside in the extent of the destabilization of native links in the extracellular half of the receptor and in the ability of 11-cis retinal to hinder such perturbations. The structural chaperone effect of 11-cis retinal reaches a maximum for cluster 2 and a minimum for cluster 4. The significant perturbation in the retinal-binding site, as highlighted by retinal deformation, suggests that cluster 4 mutants share defects in retinal binding.

Retinal Effects on the Subcellular Localization of WT and Mutated OPS

In vitro experiments in parallel to computational experiments served to determine the subcellular localization of WT and mutant OPS and RHO (Figure 4). The cDNAs were transiently transfected in COS-7 cells that expressed proteins with expected molecular weights (Figure S3A and Table S4). The use of COS-7 cells was dictated by the fact that no rod photoreceptor cell line is available that expresses rod photoreceptor genes, acquires photoreceptor morphology, and forms an outer segment in vitro. Use of a cell line that does not express OPS also allowed us to detect OPS in the WT and mutant forms using anti-OPS antibodies without the need to add tags that may affect the subcellular localization of the protein.

The ability of 9-cis and 11-cis retinal to promote proper folding and trafficking has been previously demonstrated for the adRP mutants P23H, T17M, and Q28H (Li et al., 1998; Noorwez et al., 2004, 2009; Mendes and Cheetham, 2008; Krebs et al., 2010; Kiser et al., 2014). Thus, in the present study, protein expression was carried out both in the absence and presence of 9-cis retinal. In cell culture, 9-cis retinal is more stable than the 11-cis isomer and shows similar photoactivation properties making it a good substitute (Palczewski, 2010; Kiser et al., 2014). The ER localization of OPS and RHO was quantified by the Pearson correlation coefficients (PCC) for their co-localization with the ER-resident calnexin (CLNX), a chaperon for WT and misfolded OPS (Figure S3B) (see Methods) (Kosmaoglou and Cheetham, 2008; Noorwez et al., 2009). For the WT and the G114D mutant additional confocal analyses were performed to confirm the observed differences in the PCCs (Videos S1 and S2 and Supplemental Information). Plasma membrane localization was assessed in the absence of cell permeabilization by a monoclonal antibody, RetP1, recognizing the extracellular N-terminus of the protein. Membrane integration of the expressed proteins was quantified by the RetP1/1D4 ratios, where 1D4 is a monoclonal antibody against the OPS C-terminus. The choice of cell lines does not change the outcome, as demonstrated for the P23H mutant expressed in HeLa cells where similar values of PCC and RetP1/1D4 ratio were found (Latella et al., 2016).

Most of the mutations cause increased OPS ER retention, as defined by co-localization with CLNX (1D4/CLNX in Figure 4) and confirmed by a second ER marker (Figure S4), and drastically reduced plasma membrane localization compared with the WT (RetP1 in Figure 4). Only five mutants (T4K, G51A, L125R, V137M, and A164V) falling in cluster 1 exhibit WT-like localization. These mutants show little CLNX co-localization (PCCs, 0.47–0.53) and are detected at the cell surface in nearly every OPS-expressing cell (RetP1/1D4: 0.79–0.96), indicating that they are transported to the plasma membrane (Figure S5 and Table S4). Cluster 1 mutants M44T, F45L, T58R, G89D, G106R, and C167R also show WT-like membrane localization but with significantly higher PCCs (0.58–0.65) compared with the WT, indicating that these mutations may cause partial ER retention, whereas most of the protein is properly located at the cell surface. Consistent with the high PCCs, no plasma membrane localization is observed for the mutants T17M, P23H, L46R, P53R, C110Y, G114D, P171Q, Y178C, E181K, S186P, C187Y, G188R, D190G, D190Y, H211P, H211R, and C222R, falling into clusters 2–4, which was not due to failure of the antibody to recognize misfolded mutant protein (Figure S6). Despite their high PCC values, Q28H, V87D, R135W, P180A, and P267L show some cells labeled by the RetP1 antibody in the absence of membrane permeabilization, indicating that they are partially integrated at the plasma membrane (Figures 4 and S5). Compared with the WT, these mutants have drastically reduced RetP1/1D4 values (0.05–0.29), indicating that only a small fraction of the protein is transported to the plasma membrane (Figure 5).
When expressed in the presence of 9-cis retinal, most of the mutants that exhibit strong ER retention in OPS show significantly less CLNX co-localization and increased plasma membrane localization (Figures 4 and S5). Exposing transfected cells to all-trans retinal, on the other hand, has no effect on WT RHO, the WT-like mutant G51A, and a subset of mutants that respond to 9-cis retinal, thus confirming that the observed responses are specific for a conformation of the isomer capable of binding OPS (Figure S7).

When expressed in the presence of 9-cis retinal, most of the mutants that exhibit strong ER retention in OPS show significantly less CLNX co-localization and increased plasma membrane localization (Figures 4 and S5). Exposing transfected cells to all-trans retinal, on the other hand, has no effect on WT RHO, the WT-like mutant G51A, and a subset of mutants that respond to 9-cis retinal, thus confirming that the observed responses are specific for a conformation of the isomer capable of binding OPS (Figure S7).

Subcellular localization of WT and mutants that show WT-like or only slight ER retention in the absence of retinal do not significantly change when 9-cis retinal is present (Figures 4 and S5). The strongest effect of retinal is observed for the mutants P171Q, T17M, E181K, V87D, R135W, D190Y, Q28H, P180A, and P267L, falling into clusters 2 and 3 (Figure 2), which are characterized by a strong reduction in their PCCs and an increase of their RetP1/1D4 values (Figures 4 and S5).

|     | Retinal | + 9-cis retinal |
|-----|---------|-----------------|
| WT  | ![Image](image1)
| T4K | ![Image](image2) |
| T17M| ![Image](image3) |
| P23H| ![Image](image4) |
| Q28H| ![Image](image5) |
| M44T| ![Image](image6) |
| F45L| ![Image](image7) |
| L46R| ![Image](image8) |
| G51A| ![Image](image9) |
| P53R| ![Image](image10) |
| T58R| ![Image](image11) |
| V87D| ![Image](image12) |
| G89D| ![Image](image13) |
| G106R| ![Image](image14) |
| C110Y| ![Image](image15) |
| G114D| ![Image](image16) |
| L125R| ![Image](image17) |

![Figure 4. Subcellular Localization of All Analyzed OPS Mutants in the Absence and Presence of Retinal](image)

Representative images of the WT and all analyzed OPS mutants in the absence and presence of 10 μM 9-cis retinal are shown. 1D4/CLNX: merged image of the 1D4 (anti OPS/RHO intracellular C-terminus antibody, red) and the CLNX (anti-ER antibody, green) staining; RetP1 (anti extracellular N-terminus antibody, red) staining. Scale bars, 50 μm. See also Videos S1 and S2, Table S4, and Figures S3–S7.
Among these mutants, the best phenotypic rescues in terms of plasma membrane localization are detected for T17M and V87D that, exposed to 9-cis retinal, exhibit PCCs and RetP1/1D4 values similar to WT (Figures S5C and SSD and Table S4). The mutant Q28H also shows WT-like CLNX co-localization, although this mutant still has a slightly but significantly lower RetP1/1D4 value in the presence of 9-cis retinal (Figures S5C and SSC and Table S4). The mutants P171Q, E181K, R135W, D190Y, P267L, and P180A show drastically improved membrane localization with WT-like RetP1/1D4 values; however, all of them still have slightly but significantly higher PCCs, indicating that the presence of 9-cis retinal does not completely mitigate ER retention (Figures 4 and S5). Mutants S186P, D190G, Y178C, and P23H also respond to 9-cis retinal with a significant increase in RetP1/1D4 values and a decrease in PCCs, although they still exhibit significantly reduced membrane localization and strong CLNX co-localization, suggesting less effective pharmacological rescue (Figures 4, S5C, and SSD). As for the remaining mutants, which all fall in cluster 4, the three mutants G188R, C222R, and H221P show minimal responses to 9-cis retinal in terms of membrane localization (C222R and H221P) or ER retention (G188R). ER retention of mutants L46R, P53R, C110Y, G114D, C187Y, and H211R could not be mitigated by 9-cis retinal (Figures 4 and S5).

Comparison of the PCC-RetP1/1D4 correlation plots in the absence (Figure S5E) and presence (Figure S5F) of 9-cis retinal shows that the chromophore drastically improves plasma membrane localization and reduces ER retention in a large subset of mutants. However, most of these mutants still exhibit higher ER localization than the WT, indicating that 9-cis retinal can improve proper transport but it does not fully restore the WT phenotype for many of the mutants.

Importantly, for both the OPS and RHO states, the PCC index correlates linearly with either selected or average NP scores accounting for mutation-induced impairment in the native structure network (Figures 5 and S1). The correlation is such that the NP-based clustering produces the same results if based on PCC, implying a connection between defects in structure and sub-cellular localization.

Structure-Based Discovery of a Pharmacological Chaperone Targeting the Stability Core of the OPS Protein

Structure network analysis indicated that the retinal-binding site is part of the stability core of the protein since most of the native links and hubs undergoing weakening as an effect of misfolding adRP mutations locate in that region. This inference, together with the linear correlation found between mutational impairment in the native structure network and ER retention, highlights the retinal-binding site as a suitable target for virtual screening to discover small chaperones, i.e., pharmacological chaperones able to improve the folding and routing of adRP mutants. A library of negatively charged compounds from the ZINC database (http://zinc.docking.org/ [Irwin and Shoichet, 2005; Irwin et al., 2012] see Methods) was computationally

---

**Figure 5. Linear Correlation between NP and PCC**

(A and B) The scatterplots show the linear correlation between the NP accounting for mutational effects on the native structure network and the PCC index accounting for ER retention in the OPS (A) and RHO (B) states. The linear regression equations are PCC = 0.014NP + 0.071, r = 0.932 for OPS and PCC = 0.012NP + 0.273, r = 0.938 for RHO. The error-weighted correlation coefficients are 0.910 for OPS and 0.960 for RHO. The colors of circles reflect the structural cluster assignment for each mutant (see the legend to Figure 2). See also Figure S2.
screened against the retinal-binding site using the Glide software (Friesner et al., 2004, 2006). Compounds were primarily filtered according to the docking score leading to one hit list (made of 1,000 compounds) per docking run (i.e., onto different structures). Vdif served as an additional index to select compounds that in addition to a relatively good docking score had a relatively high Vdif relative to 11-cis retinal (see Methods).

It is worth noting that volume comparisons were performed for compounds taken in their docking/interaction mode with the protein. The index therefore accounts both for shape similarity between each ligand and 11-cis retinal and for their degree of overlap in the binding site (see Methods). In this respect, Vdif cannot be considered a canonical ligand-based index.

Twenty compounds (Table S7) of a list of 254 hits checked for commercial availability were probed in vitro for their ability to favor plasma membrane localization of T17M, the mutant from cluster 2 most responsive to retinal. Like retinal, all the selected compounds except one had predicted octanol/water partition coefficients, i.e., xlogP, ≥ 5 (the xlogP of 11-cis retinal is 5.80 [http://zinc.docking.org/]).

The same experimental conditions as those used in this study to test the effects of 9-cis retinal were applied for in vitro compound screening. One compound, 5,8-epoxy-13-cis retinoic acid (hereafter named 13-cis-5,8-ERA [Table 1], compound 1 in Table S7) was able to mitigate ER retention and promote plasma membrane localization of T17M (Figure 6A). The PCC and RetP1/1D4 indices in the presence of 10 μM 13-cis-5,8-ERA are, respectively, 0.50 and 0.60, similar to 9-cis retinal, 0.46 and 0.59 (Tables S8 and S9).

The 13-cis-5,8-ERA, which comprises a mixture of commercially available optical isomers (i.e., 5S8R, 5R8S, 5R8R, and 5S8S), proved effective as a pharmacological chaperone also for the P23H mutant from cluster 3 (Figure 6B) and another mutant from cluster 2, E181K (Figure 6C). P23H was tested because it is the adRP mutant most studied in vivo (Comitato et al., 2016; Sakami et al., 2011, 2014; Chiang et al., 2015), whereas E181K was selected for testing based on the hypothesis that the substituting lysine would stabilize the protein-chaperone complex through an additional intermolecular salt bridge.

The Tanimoto coefficient (based on RDKit circular Morgan fingerprints [1,024 bits]) accounting for the similarity between 13-cis-5,8-ERA and 11-cis retinal is 0.588 (Table S7), which is lower than the cutoff suitable to cluster compounds according to chemical similarity. Thus, according to the Tanimoto coefficient, among the 20 selected compounds, 13-cis-5,8-ERA is the most similar to 11-cis retinal; however, the similarity is not so striking as also indicated by the Vdif index.

To quantitatively compare the pharmacological chaperone activity of 13-cis-5,8-ERA with that of 9-cis retinal, for the three adRP mutants the EC50 values were computed relative to the PCC and RetP1/1D4

## Table 1. EC50 Values with Respect to PCC and RetP1/1D4 Immunostaining Comparing 9-cis Retinal and 13-cis-5,8-ERA

| In Vitro Effect | T17M | P23H | E181K |
|-----------------|------|------|-------|
|                 | EC50<sub>Ret</sub> | EC50<sub>ERA</sub> | EC50<sub>Ret</sub> | EC50<sub>ERA</sub> | EC50<sub>Ret</sub> | EC50<sub>ERA</sub> |
| PCC             | 8.0  | 9.8  | 17.3  | 9.3  | 9.4  | 4.5   |
| RetP1/1D4       | 5.4  | 4.6  | 8.0   | 4.8  | 1.1  | 0.5   |

EC50<sub>Ret</sub> and EC50<sub>ERA</sub> are, respectively, the μM EC50 values of 9-cis retinal and 13-cis-5,8-ERA relative to ER retention (accounted for by PCC) and plasma membrane localization (accounted for by RetP1/1D4 immunostaining) of T17M, P23H, and E181K mutants. A mixture of four optical isomers of 13-cis-5,8-ERA was employed in EC50 determinations. See also Table S7.
indices (Figures 6D–6I and Table S8). The 13-cis-5,8-ERA compound is slightly less effective than 9-cis retinal toward the T17M mutant, especially with regard to the effect on ER retention (Table 1 and Figures 6D and 6G), whereas its effectiveness toward P23H and E181K is 2-fold higher than that of 9-cis retinal both in mitigating ER retention (Table 1 and Figures 6E and 6F) and promoting plasma membrane localization (Table 1 and Figures 6H and 6I).

Figure 6. Effects of 13-cis-5,8-ERA on Three Mutants
(A–C) Representative immunofluorescence images depicting the subcellular localization of T17M (A), P23H (B), and E181K (C) mutants in the OPS state (i.e., -9-cis retinal), in the presence of 10 μM 9-cis retinal, and in the presence of 10 μM 13-cis-5,8-ERA. CLNX/1D4: merged image of the anti-CLNX antibody staining (green) and the anti-OPS/RHO 1D4 antibody staining against the intracellular C-terminus (red); RetP1: staining of membrane localized OPS/RHO with the RetP1 antibody against the extracellular N-terminus. Scale bars, 50 μm.

(D–I) COS-7 transfected cells were exposed to different concentrations of 9-cis retinal (black circles) or 13-cis-5,8-ERA (black squares). Values are the means (±SD) from the analysis of at least ten transfected cells from three independent experiments. PCC values were derived from the analysis of co-localization of calnexin and OPS/RHO (CLNX/1D4) for the T17M (D), P23H (E), and E181K (F) mutants. Ratios of RetP1-positive cells and 1D4-positive cells were computed for the T17M (G), P23H (H), and E181K (I) mutants.

See also Table S8.

The 13-cis-5,8-ERA from the screened library corresponds to the SS8R isomer. To better characterize the effect of the compound on the native structure network of the protein, the other three isomers were docked into the retinal-binding site as well. The complexes between WT and mutated forms and the four distinct isomers were subjected to MD simulation and PSN analysis, following the protocol set in this study. In all complexes, the carboxylate of 13-cis-5,8-ERA establishes charge-reinforced H-bonds with S186 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9). The olefinic chain of the ligand makes van der Waals interactions with I189 (in EL2), Y268 (in H6), and K296 (in H7) (Figures 7, S8, and S9). A peculiarity of the E181K mutant is the formation of an additional salt bridge between the substituting amino acid and the carboxylate of the ligand (Figures S8 and S9).
isomers occur at the bicyclic end. Collectively, while occupying the same binding site, 13-cis-5,8-ERA and 11-cis retinal display divergent interactions (Figure S9).

To mimic in vitro determinations, which were carried out on a mixture of isomers, the structural chaperone effect of 13-cis-5,8-ERA on T17M, P23H, and E181K mutants was described by an NP score averaged over the scores of the single isomers, i.e., 25 \pm 4.54 for T17M, 32.91 \pm 4.66 for P23H, and 26.35 \pm 4.12 for E181K. The average NP scores of the new compound relative to the three mutants are consistent with the effect of the compound on ER retention as accounted for by PCC. In line with the demonstrated ability of 13-cis-5,8-ERA to relieve ER retention and improve plasma membrane localization for all three mutants, the number of
native links undergoing a reduction in frequency ≥ 25% is significantly lower in the presence of the compound compared with the OPS state (Figure 7). For P23H and E181K, the average structural chaperone effect of the four isomers is greater than that of retinal, in line with in vitro EC50 determinations (Figures 6 and 7).

To validate the predictions from computational experiments that 13-cis-5,8-ERA docks at the retinal-binding site, the binding of the compound to OPS was evaluated by monitoring the changes in OPS tryptophan (Trp) fluorescence with varied concentrations of the ligand. The changes in the Trp fluorescence reflect the conformational changes in the chromophore-binding pocket induced upon ligand binding (Farrens and Khorana, 1995). A typical quenching of fluorescence associated with W265 was noted upon treatment with increasing concentrations of 9-cis retinal (Figure 8A). 13-cis-5,8-ERA displayed a similar quenching pattern (Figure 8B). This finding suggests that 13-cis-5,8-ERA either binds to the chromophore-binding pocket or exerts an allosteric binding affect that can lead to conformational changes in the chromophore-binding pocket. The EC50 of 13-cis-5,8-ERA to OPS (8.6 ± 0.2 nM) was 14-fold lower compared with 9-cis retinal (123.9 ± 7.0 nM) (Figures 8A and 8B). Additionally, we tested the effect of 13-cis-5,8-ERA on the regeneration rate of iso-rhodopsin pigment by using time-dependent UV-Vis spectroscopy. As expected, addition of 9-cis-retinal to OPS membranes resulted in the Schiff base formation (λmax = 487 nm) between 9-cis retinal and K296 (Figure 8C, red trace). However, pre-treatment of OPS membranes with 10 molar excess of 13-cis-5,8-ERA resulted in a significant decrease in both the iso-rhodopsin regeneration rates (t1/2 = 3.4233 ± 0.716 min compared with 1.3694 ± 0.848 min for 9-cis retinal) and the total iso-rhodopsin formation (88.04 ± 2.39% relative to 9-cis retinal alone) (Figures 8C and 8D). The ability of
9-cis retinal to bind 13-cis-5,8-ERA pre-treated OPS and to form iso-rhodopsin pigment suggests a reversible binding of 13-cis-5,8-ERA to the protein. Overall, these findings suggest that 13-cis-5,8-ERA induces a conformational change in the OPS chromophore-binding pocket and might compete with 9-cis-retinal for OPS binding.

In summary, virtual screening of compound libraries led to the discovery of a pharmacological chaperone more effective than retinal toward three adRP mutants selected from the most responsive clusters. The compound was not revealed by previous virtual screening of the same proteins, owing to different computational conditions and the selected libraries (Noorwez et al., 2008). The ability of the novel chaperone to relieve perturbations in the native structure network is consistent with its ability to correct routing of the mutated protein. The combination of molecular simulations, sub-cellular localization by immunohistochemistry, and binding detection by biophysical assays indicates that the chaperone activity of 13-cis-5,8-ERA is due to the establishment of distinct intermolecular interactions with amino acids in the retinal-binding site.

DISCUSSION

Retinitis pigmentosa is a composite of varied retinal dystrophies most frequently leading to inherited blindness. Although progress has been made in understanding the genetic basis of the disease, the development of effective therapeutic interventions is still lacking. adRP linked to mutations in the GPCR RHO are part of the family of conformational diseases, whose structural determinants are still unknown (reviewed in Conn and Ulloa-Aguirre, 2010).

Pharmacological chaperones are promising therapeutic agents for the treatment of misfolding diseases linked to missense mutations. They consist of small molecules that enter cells, specifically bind to misfolded mutant proteins, and stabilize them in a conformational state that allows passing ER quality control systems (Conn and Ulloa-Aguirre, 2010; Ulloa-Aguirre et al., 2004; Bernier et al., 2004). The discovery and development of such therapeutic agents cannot be accomplished without significant knowledge of the structural defects engendered by the various mutations.

In the present study, WT and 33 adRP mutants were subjected to parallel in silico and in vitro experiments aimed at characterizing and quantifying mutational effects on structural stability and ER retention of the protein, ultimately establishing a connection between the two distinct levels of analysis. The working hypothesis motivating our computational experiments is that adRP mutants classified as misfolded indeed represent “quasi-native” states of OPS.

The analysis of molecular simulations relied on structure network parameters (i.e., hubs and links) as a strategy to study issues of protein structure instability likely pertaining to conformational diseases (Fanelli and Seeber, 2010). In this context, equilibrium MD simulations at 300 K and melting temperatures were instrumental in investigating mutational effects on the native structure networks of the RHO and OPS states. Employing the native structure network as a frame of reference helped to describe mutational effects in terms of quantifiable impairments in the intramolecular interactions characterizing the native state. We observed that in the absence of 11-cis retinal the majority of the 33 adRP mutants show marked impairment in stable native hubs and links as an effect of mutation on the backbone and side-chain structures and dynamics. In the presence of 11-cis retinal, such perturbations decrease significantly for a subset of mutants. This agrees with other evidence that OPS is less stable than RHO even in the native state (Khan et al., 1991). A computational index, NP, quantifying mutation-induced impairment in the native structure networks of both OPS and RHO served to structurally classify the 33 different mutants. Such clustering permitted the identification of common structural traits despite different mutations. Those traits were embodied in those native links that become less stable as an effect of mutation. These signatures are crude in that they depict an average behavior, with the understanding that each mutant has its own structural distinctions. Yet, we preferred to focus on common structural effects of mutations from the same cluster to achieve a structure-based classification of adRP mutants with therapeutic implications.

In vitro experiments served to determine the subcellular localization of WT and mutant forms of OPS in the absence and presence of 9-cis retinal, which led to the development of an index of ER retention (PCC) based on co-localization of OPS/RHO and calnexin. The finding of a linear correlation between NP and
PCC indices led us to associate the structural signatures of each cluster of mutants with the tendency toward ER retention, an important step toward connecting defects in structure and subcellular localization. Indeed, in the OPS state, cluster 1 mutants tend to share the lowest hub and link weakening compared with the other clusters, especially in the extracellular regions, which may relate to their lowest ER retention and highest plasma membrane localization compared with the other mutants. Marked ER retention and low plasma membrane localization for clusters 2, 3, and 4 are instead associated with hub and link weakening in both the extracellular and intracellular portions. The distinction between these three clusters, with emphasis on clusters 2 and 4, essentially relies on the effect of retinal. The in vitro chaperone effect of retinal on cluster 2 mutants is likely related to the ability of the chromophore to prevent major mutational effects on the native structure network. In comparison, the inability of retinal to exert a chaperone effect for cluster 4 mutants is likely due to the inability of the chromophore to properly bind and establish native connections with the protein. Indeed, for these mutants link weakening involves the retinal itself, core-facing nodes in the extracellular regions of H2 (T94 and S98), H3 (E113 and T118), H5 (F203 and V204), H6 (C264, W265, Y268, V271, and I275), and H7 (M128, T287, M288, F293, A295, K296, and T297), as well as nodes on both the N-terminus (T4, F9, P12, N15, V20, F24, Y30, A32) and EL2 (W175, P180, K181, C185, P186, I189, D190, Y191, T192, T193, P194, and N200). Previously, some of these residues had been predicted to participate in the stability core of the protein (Rader et al., 2004). Link weakening in the retinal-binding site for cluster 4 mutants nicely relates to retinal deformation as indicated by the Vout size/shape descriptor, thus strengthening the hypothesis that retinal cannot bind such mutants properly in line with early in vitro evidence from retinal reconstitution experiments (reviewed in Briscoe et al., 2004; Krebs et al., 2010; Rakoczy et al., 2011; Athanasiou et al., 2018). The structural and cellular behaviors of cluster 3 mutants lie between those of clusters 2 and 4.

Thus the integration of atomic and subcellular levels of analysis led to the finding that the structural stability of the protein, impaired as an effect of mutations, correlated with ER retention. The quantitative relation between structural deviation from the native state and ER retention is of remarkable value since ER retention has been correlated with the pathological phenotype in published studies, although limited to a subset of the mutants analyzed here (Kosmaoglou et al., 2009; Krebs et al., 2010; Griciuc et al., 2011; Comitato et al., 2016).

The correlation between NP and PCC scores implies that the classification of mutants based on their structural impairment is consistent with the classification based on their ER retention. Mutational effects on ER retention and the ability of OPS to bind retinal underlie earlier classifications of adRP RHO mutants (reviewed in Briscoe et al., 2004; Krebs et al., 2010). Our in vitro data on the OPS states are substantially in agreement with previous characterizations of subcellular localization in the absence of retinal (reviewed in Briscoe et al., 2004; Krebs et al., 2010). Apparent discrepancies regard two mutants (L125R and C167R) assigned to Krebs class II but localized at the membrane in this study and one mutant (L46R) assigned to class I but retained in the ER in this study. In contrast, few discrepancies concern the response to retinal that relies on a completely different approach in the present study. Previous studies evaluated the ability of the protein to regenerate with retinal, as detected by spectroscopic analyses, whereas the present study evaluated the ability of retinal to influence the subcellular localization of the mutants. In this study, five (P171Q, Y178C, E181K, S186P, and D190Y) of eleven (C110Y, G114D, P171Q, Y178C, E181K, S186P, C187Y, D190Y, H211P, H211R, and C222R) mutants previously found incapable of binding retinal (Krebs et al., 2010) were localized in the ER in the OPS form but could improve their plasma membrane distribution and relieve ER retention as an effect of retinal.

Another classification, which has been recently updated, divides RHO mutants into seven classes (classes 1–7). Class 2 encompasses those mutants considered as misfolded because of their ER retention and inability to reconstitute with retinal, whereas the other classes contain mutants thought to be properly folded but impaired in different aspects of function (Athanasiou et al., 2018). Consistently, cluster 2, 3, and 4 mutants from this study, which are retained in the ER at least in their OPS form, fell into class 2. Consistency was also found for a number of mutants in our clusters 1 and 2, which fall in classes 3 (R135W), 4 (T4K and T17M), 5 (M44T and V137M), and 7 (F45L) by Athanasiou and co-workers and include also a mutant considered as a benign single mutant polymorphism (G51A) (Athanasiou et al., 2018). Indeed, for such mutants that show plasma membrane localization at least in their RHO form, defects other than ER retention may cause the pathologic phenotype. In contrast, six of the eleven mutants in...
our cluster 1 (T58R, G89D, G106R, L125R, A164V, C167R), which are moderately retained in the ER in the OPS form, are considered misfolded by Athanasiou and co-workers and ascribed to class 2 (Athanasiou et al., 2018).

Early mass spectrometry determinations on four adRP mutants postulated partial (for G89D and A164V) or complete (for L125R and P211H) misfolding of OPS owing to the formation of a non-native disulfide bridge between C185 and C187 in EL2 (Hwa et al., 2001). Three of those mutants fall on our cluster 1, suggesting that, if present, such an intra-loop disulfide bridge would remain compatible with a protein quasi-native state properly targeted to the plasma membrane.

Collectively, this investigation revealed some retinal responsiveness in the majority of the 33 adRP mutants, including a number of mutants previously classified as misfolded. This supports our working hypothesis that such mutants indeed represent quasi-native states of the OPS protein still capable of binding retinal.

The results of the integrated in silico and in vitro analyses suggest that ER retention and compromised plasma membrane localization of OPS are related to the loss or weakening of native connections involving the retinal-binding site as well as highly conserved nodes in the cytosolic regions. These findings support a structural communication whereby mutations exert long-range destabilizing effects on common nodes and links in the structure network necessary for the stability of the protein. Therefore, the putative stability core of the protein inferred from PSN analysis was targeted by virtual screening of over 300,000 anionic compounds. Mutant clusters based on structure network impairment were exploited to select three retinal-responsive mutants, i.e., T17M, P23H, and E181K from clusters 2 and 3, for in vitro analyses. One compound, an oxidation product of the 13-cis retinoic acid (Liang et al., 2003), 13-cis-5,8-ERA, of 20 tested compounds proved able to relieve ER retention and favor the plasma membrane localization of all three mutants. For E181K and, to a lesser extent, P23H, the pharmacological chaperone action of 13-cis-5,8-ERA was 2-fold greater than that of 9-cis retinal. For the E181K mutant, the enhanced effect may be due, at least in part, to the formation of an additional intermolecular salt bridge between the substituting lysine and the carboxylate of the ligand. The chaperone action of 13-cis-5,8-ERA is likely due to its ability to stabilize OPS by occupying in a reversible manner the retinal-binding site. The compound was tested as a mixture of four optical isomers reflecting the presence of two chiral centers on the condensed bicyclic group. MD simulations of the four distinct isomers toward the three mutants revealed divergences solely in the binding mode of the bicyclic moiety, the carboxylate site showing overlapping binding modes in the different isomers. This suggests that isomer separation may lead to some improvement in the chaperone activity of the compound. The average effect of the four isomers on relieving native link weakening caused by the mutation is in line with in vitro observations, thus highlighting the ability of the graph-based approach to infer the structural bases of conformational diseases linked to missense mutations.

In summary, ER retention and compromised plasma membrane localization shared by most of the mutants considered in this study are related to the loss or weakening of native intramolecular interactions involving the retinal-binding site as well as highly conserved amino acids in the cytosolic regions. These structural effects can be variably attenuated by retinal unless perturbations cause significant deformations in the retinal-binding site thus compromising proper binding of the chromophore. Several adRP mutants, especially those in clusters 2 and 3, are amenable to treatment with pharmacological chaperones that limit ER retention and subsequent ER stress by improving structural stability and routing of OPS. Together these data suggest that the majority of the ER-retained adRP RHO mutants considered in this study hold “quasi-native” structures that can be stabilized by small compounds able to establish specific interactions with the retinal-binding site. On this basis, by targeting the putative stability core of the protein, we discovered a reversible orthosteric inhibitor of retinal binding able to correct the misrouting of three adRP mutants from clusters 2 and 3, T17M, P23H, and E181K. For P23H and E181K the compound is more effective than 9-cis retinal as a chaperone. Virtual screening allowed reduction by more than four orders of magnitude the number of compounds necessary for in vitro testing, ultimately leading to the discovery of a promising pharmacological chaperone from more than 300,000 compounds screened in silico and 20 compounds screened in vitro.

The present study generated the tools for discovering and designing small compounds able to mitigate the structural destabilization caused by misfolding mutations. A promising pharmacological chaperone has been discovered, which holds the potential to be translated into a therapeutic agent for adRP linked to
RHO mutations. The comprehensive analysis of adRP mutations derived from this study also may be valuable for researchers developing new therapeutic approaches based on small chaperones. The strategy described here to discover a small chaperone can be applied to various conformational diseases linked to missense mutations of proteins with known structure.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Transparent Methods, nine figures, nine tables, and two videos and can be found with this article online at https://doi.org/10.1016/j.isci.2018.05.001.

ACKNOWLEDGMENTS
We acknowledge the CIGS of the University of Modena for providing confocal microscopy assistance. This study was supported by Telethon-Italy grant [GGP11210] and by Fondazione Roma grant (call for proposals 2013 on Retinitis Pigmentosa) to both F.F. and V.M. This research was supported in part by grants from the National Institutes of Health (EY009339, EY027283, and EY024864 to K.P.). K.P. is the John H. Hord Professor of Pharmacology.

AUTHOR CONTRIBUTIONS
P.B. performed the site-directed mutagenesis of RHO cDNA and the in vitro characterization of the 33 adRP mutants. A.F. implemented and performed the PSN analyses. A.C. and M.T.D.S. performed the in vitro screening of compounds. F.R. conducted the virtual screening and performed docking simulations. V.M. designed the strategy for in vitro analyses. F.F. conceived the study, ran molecular simulations, conducted virtual screenings, and performed structural analyses and compound selection. S.G. and S.K. performed the opsin binding assays. P.B., A.F., V.M., F.F., S.G., S.K., and K.P. contributed to writing and editing the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.
plasma membrane. Insights for pharmacoperone drugs. Trends Endocrinol. Metab. 21, 190–197.

De Benedetti, P.G., and Fanelli, F. (2010). Computational quantum chemistry and adaptive ligand modeling in mechanistic GPCR Drug Discov. Today 15, 859–866.

Fanelli, F., and De Benedetti, P.G. (2011). Update 1 of computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem. Rev. 111, PR438–PR535.

Fanelli, F., Felline, A., and Raimondi, F. (2013). Network analysis to uncover the structural communication in GPCRs. Methods Cell Biol. 117, 43–61.

Fanelli, F., and Seeber, M. (2010). Structural insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants. FEBS J. 276, 3196–3209.

Farrens, D.L., and Khorana, H.G. (1995). Structure and function in rhodopsin: mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants. Proc. Natl. Acad. Sci. USA 92, 4872–4876.

Hwa, J., Klein-Seetharaman, J., and Khorana, H.G. (2001). Structure and function in rhodopsin: further elucidation of the role of the intradiscal cysteines, Cys-110, -185, and -187, in rhodopsin folding and function. Proc. Natl. Acad. Sci. USA 98, 1932–1935.

Hwa, J., Reeves, P.J., Klein-Seetharaman, J., Davidson, F., and Khorana, H.G. (1999). Structure and function in rhodopsin: insights into retinitis pigmentosa from unfolding simulations of rhodopsin mutants. FEBS J. 276, 3196–3209.

Iannaccone, A., Man, J., Waseem, N., Jennings, B.J., Ganapathiraju, M., Gallacher, K., Reese, E., Bhattacharya, S.S., and Klein-Seetharaman, J. (2006). Retinitis pigmentosa associated with rhodopsin mutations: correlation between phenotypic variability and molecular effects. Vision Res. 46, 4556–4567.

Irwin, J.J., and Shoichet, B.K. (2005). ZINC—a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177–182.

Irwin, J.J., Sterling, T., Mysinger, M.M., Bolstad, E.S., and Coleman, R.G. (2012). ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52, 1757–1768.

Kaushal, S., and Khorana, H.G. (1994). Structure and function in rhodopsin: 7. Point mutations associated with autosomal dominant retinitis pigmentosa. Biochemistry 33, 6121–6128.

Kennon, A., Aherne, A., and Humphries, P. (2005). Light in retinitis pigmentosa. Trends Genet. 21, 103–110.

Khan, S.M.A., Bole, W., Hargrave, P.A., Santoro, M.M., and Mcdowell, J.H. (1991). Differential scanning calorimetry of bovine rhodopsin in rod outer-segment disk membranes. Eur. J. Biochem. 200, 53–59.

Kiser, P.D., Golczak, M., and Palczewski, K. (2014). Chemistry of the retinoid (visual) cycle. Chem. Rev. 114, 194–232.

Kosmaoglou, M., and Cheetham, M.E. (2008). Calnexin is not essential for mammalian rod opsin biogenesis. Mol. Vis. 14, 2466–2474.

Kosmaoglou, M., Kanuga, N., Aguila, M., Garriga, P., and Cheetham, M.E. (2009). A dual role for EDEM in the processing of rod opsin. J. Cell Sci. 122, 4465–4472.

Krebs, M.P., Holden, D.C., Joshi, P., Clark, C.L., 3rd, Lee, A.H., and Kaushal, S. (2010). Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J. Mol. Biol. 395, 1063–1078.

Latella, M.C., Di Salvo, M.T., Cocichiarella, F., Benati, D., Gissend, G., Comitato, A., Mango, V., and Recchia, A. (2016). Electroporation of plasmid-based CRISPR/Cas9 in the mouse retina. Mol. Ther. Nucleic Acids 5, e389.

Li, J., Edwards, P.C., Burghammer, M., Villa, C., and Schertler, G.F. (2004). Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343, 1409–1438.

Li, T., Sandberg, M.A., Pavlyk, B.S., Rosner, B., Hayes, K.C., Dryja, T.P., andchain, E.L. (1998). Effect of vitamin A supplementation on rhodopsin mutants threonine-17–> methionine and proline-347–> serine in transgenic mice and in cell cultures. Proc. Natl. Acad. Sci. USA 95, 11933–11938.

Liang, Y., Fotiadi, D., Filipek, S., Saperstein, D.A., Palczewski, K., and Engel, A. (2003). Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278, 21655–21662.

Lin, J.C., and Liu, H.L. (2006). Protein conformational diseases: from mechanisms to drug designs. Curr. Drug Discov. Technol. 3, 145–153.

Mendes, H.F., and Cheetham, M.E. (2008). Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum. Mol. Genet. 17, 3043–3054.

Mendes, H.F., Van Der Spuy, J., Chapple, J.P., and Cheetham, M.E. (2005). Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol. Med. 11, 177–185.

Mizragedeg, T., Benko, G., Filipek, S., and Palczewski, K. (2003). Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42, 2759–2767.

Noorwez, S.M., Malhotra, R., Mcdowell, J.H., Smith, K.A., Krebs, M.P., and Kaushal, S. (2004). Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J. Biol. Chem. 279, 16278–16284.

Noorwez, S.M., Ostrov, D.A., Mcdowell, J.H., Krebs, M.P., and Kaushal, S. (2008). A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Invest. Ophthamol. Vis. Sci. 49, 3224–3230.

Noorwez, S.M., Sama, R.R., and Kaushal, S. (2009). Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal. J. Biol. Chem. 284, 33333–33342.

Palczewski, K. (2006). G protein-coupled receptor rhodopsin. Annu. Rev. Biochem. 75, 745–767.

Palczewski, K. (2010). Retinoids for treatment of retinal diseases. Trends Pharmacol. Sci. 31, 284–295.

Palczewski, K., Kumaksa, T., Hori, T., Behnke, C.A., Motoshima, H., Fox, B.A., Le Trong, I., Teller, D.C., Okada, T., Stenkamp, R.E., et al. (2000). Crystal structure of bovine rhodopsin. Science 289, 739–745.
Park, J.H., Scheerer, P., Hofmann, K.P., Choe, H.W., and Ernst, O.P. (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183–187.

Rader, A.J., Anderson, G., Isin, B., Khorana, H.G., Bahar, I., and Klein-Seetharaman, J. (2004). Identification of core amino acids stabilizing rhodopsin. Proc. Natl. Acad. Sci. USA 101, 7246–7251.

Rakoczy, E.P., Kiel, C., Mckeone, R., Stricher, F., and Serrano, L. (2011). Analysis of disease-linked rhodopsin mutations based on structure, function, and protein stability calculations. J. Mol. Biol. 405, 584–606.

Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., Thian, F.S., Choe, P.S., Pardon, E., California, D., et al. (2011). Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. Nature 469, 175–181.

Sakami, S., Kolesnikov, A.V., Kefalov, V.J., and Palczewski, K. (2014). P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. Hum. Mol. Genet. 23, 1723–1741.

Sakami, S., Maeda, T., Bereta, G., Okano, K., Golczak, M., Sumaroka, A., Roman, A.J., Cideciyan, A.V., Jacobson, S.G., and Palczewski, K. (2011). Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J. Biol. Chem. 286, 10551–10567.

Sanders, C.R., and Myers, J.K. (2004). Disease-related misassembly of membrane proteins. Annu. Rev. Biophys. Biomol. Struct. 33, 25–51.

Scheerer, P., Park, J.H., Hildebrand, P.W., Kim, Y.J., Krauss, N., Choe, H.W., Hofmann, K.P., and Ernst, O.P. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502.

Stojanovic, A., Hwang, I., Khorana, H.G., and Hwa, J. (2003). Retinitis pigmentosa rhodopsin mutations L125R and A164V perturb critical interhelical interactions: new insights through compensatory mutations and crystal structure analysis. J. Biol. Chem. 278, 39020–39028.

Tam, B.M., and Moritz, O.L. (2009). The role of rhodopsin glycosylation in protein folding, trafficking, and light-sensitive retinal degeneration. J. Neurosci. 29, 15145–15154.

Ulloa-Aguirre, A., Janovick, J.A., Brothers, S.P., and Conn, P.M. (2004). Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5, 821–837.

Vishveshwara, S., Ghosh, A., and Hansia, P. (2009). Intra and inter-molecular communications through protein structure network. Curr. Protein Pept. Sci. 10, 146–160.
Supplemental Information

A Small Chaperone Improves Folding and Routing of Rhodopsin Mutants Linked to Inherited Blindness

Petra Behnen, Angelo Felline, Antonella Comitato, Maria Teresa Di Salvo, Francesco Raimondi, Sahil Gulati, Shirin Kahremany, Krzysztof Palczewski, Valeria Marigo, and Francesca Fanelli
Supplemental Information
Figure S1 (related to Figure 2). Linear correlation between the NP score computed for the RHO state and the spectroscopic \( A_{280}/A_{500} \) index. The linear regression equation is \( A_{280}/A_{500} = 0.035NP + 0.461, r = 0.84 \). The colors of the circles reflect the assignment of mutants to different structural clusters (see the legend to Figure 2).
Figure S2 (related to Figures 2 and 5). Mutant clustering based on the average NP scores. Plots of the NP scores averaged over three values derived from independent simulations of OPS (A) and RHO (B), and the difference between them (ΔNP (C)) are shown. Colors indicate the four clusters obtained by using the average NP scores and the Δ between them. White, blue, gray, and black indicate, respectively, clusters 1, 2, 3, and 4. (D) The average of the members of a cluster based on NPs is shown for OPS and RHO. The linear correlations between average NP score and PCC for OPS (E) and RHO (F) states are also shown. The linear regression equations are PCC = 0.015 average NP + 0.033, r = 0.900, for OPS, and PCC = 0.014 average NP + 0.215, r = 0.950, for RHO. The colors of the circles reflect the assignment of mutants to different structural clusters (see the legend to Figure 2).
Figure S3 (related to Figure 4). Immunoblot and OPS/CLNX-colocalization analyses of COS7 cells transiently transfected with WT or mutant OPS. (A) Immunoblot analysis of WT OPS and mutants T17M, G51A, G114D, P171Q and P180A. Equal amounts of protein extracts from cells expressing WT or mutant OPS were subjected to western blot analysis and probed using the 1D4 antibody as described previously (Komolov et al., Anal Bioanal Chem, 397, 2967 (2010)). RHO extracted from a human donor retina (lane C), COS-expressed WT, and mutants G51A, G114D, P171Q and P180A run at molecular mass values of ~36 kDa independent of the presence (+) or absence (-) of retinal (black arrow). The lower molecular weight band of T17M (white arrow) most likely reflects the previously described glycosylation status of OPS (Tam and Moritz, J Neurosci, 29, 15145 (2009)). Anti-Neomycin Phosphotransferase 2 expression was used as a control of the transfection efficiency for WT and mutant OPS (gray arrow). (B) Examples of OPS/CLNX-colocalization analyses in COS7 cells transiently transfected with WT (left panel) or mutant G114D OPS (right panel) constructs. Red/green: merged anti-OPS (1D4 antibody, red) and anti-CLNX (green) immunofluorescence images showing low (WT) and high (G114D) PCC-values respectively. Green: green channels showing the corresponding anti-CLNX immunofluorescence. Red: red channel showing the anti-OPS immunofluorescence. ROI: merged image of the region of interest (ROI) for PCC evaluation, which was selected by free hand drawing around the signal in the red channel. Red vs. green: scatterplots of red and green pixel intensities. The scatterplot on the left-hand side (WT) shows separation of the green and red channels (PCC = 0.339). The scatterplot on the right-hand side (G114D) shows strong overlap of the two channels (PCC = 0.938).
Figure S4 (related to Figure 4). Co-localization analysis of WT and selected OPS mutants with the ER resident double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK). Shown are representative immunofluorescence images, after expression in the absence of retinal, of the WT, the WT-like mutant G51A, and the four mutants T17M, G114D, P171Q, and P180A with the 1D4 antibody (red) that binds an epitope localized at the intracellular C-term of OPS and an anti-PERK antibody (green). These mutants showed strong CLNX co-localization when expressed in the absence of retinal (see Figure 4). In agreement with the observations reported in Figure 4 and Table S4 (showing co-localization analyses with CLNX) WT and G51A OPS poorly co-localized with PERK with PCC values of 0.40 ± 0.05 and 0.43 ± 0.04 respectively, whereas significant (P ≤ 0.001) co-localization was observed for the mutants T17M (PCC: 0.79 ± 0.03), G114D (PCC: 0.80 ± 0.02), P171Q (PCC: 0.73 ± 0.02) and P180A (PCC: 0.71 ± 0.03). Scale bar = 50 μm.
Figure S5 (related to Figure 4). Inverse correlation of plasma membrane localization and ER-retention of mutants. Summary of calculated PCC- and RetP1/1D4-values for WT and for all analyzed mutants expressed in the absence (A, C) or presence (B, D) of 10 μM 9-cis retinal. The correlation plots of RetP1/1D4-values (x-axis) and PCC-values (y-axis) in the absence (E) or presence (F) of 9-cis retinal are shown. Data represent the mean ± SE of 3-5 experiments. Statistical analyses for each mutant compared to the WT were performed by two-sample t-Student test. * P ≤ 0.05; ** P ≤ 0.01; ***P ≤ 0.001.
Figure S6 (related to Figure 4). Ability of the RetP1 antibody to recognize misfolded mutant OPS. Shown are representative immunofluorescence images of COS cells expressing WT and OPS mutants after permeabilization of the cell membrane and immunostaining with the RetP1 antibody. In COS cells that expressed WT OPS a uniformly distributed RetP1 staining was detected, independent of the absence or presence of retinal (+RET). In the case of mutants T17M, P23H, L46R, P53R, C110Y, G114D, P171Q, Y178C, E181K, S186P, C187Y, G188R, D190G, D190Y, H211P, H211R, and C222R, that showed no membrane localization in the absence of retinal (see Figure 4), significant RetP1 staining around the nuclei was detected after permeabilization of the cell membrane. Significant RetP1 staining of intracellular opsins also was detected with the OPS mutants L46R, C119Y, G114D, and H211R, after expression in the presence of retinal and permeabilization of the cell membrane. These mutants showed no plasma membrane localization in the presence of retinal (see Figure 4). Scale bars = 50 μm.
Figure S7 (related to Figure 4). All-trans retinal has no effect on the subcellular localization of WT OPS and a subset of OPS mutants. Shown are representative immunofluorescence images of WT OPS, the WT-like mutant G51A, and the three mutants T17M, P171Q, and P180A in the presence of 10 μM all-trans retinal (A). CLNX/1D4: merged image of the CLNX- (green) and 1D4-(red) immunostaining; RetP1: antibody binding an epitope localized at the extracellular N-terminal of OPS allowing detection of membrane localized OPS. Histograms showing the analyzed PCC- (B) and RetP1/1D4 (C) values. WT OPS and the analyzed mutants showed no differences in subcellular localization in the absence or presence of all-trans retinal confirming that the responses to 9-cis retinal seen for T17M, P171Q and P180A (see Figures 4 and S6) are specific. Scale bars = 50 μm.
Figure S8 (related to Figure 8). Complexes between the four distinct optical isomers of 13-cis-5,8-ERA and the OPS chromophore-binding site. Selected details of the interactions between 13-cis-5,8-ERA and WT (A), T17M (B), P23H (C), and E181K (D) extracted from the average minimized structures are shown. For each mutant OPS, the complexes with the four different isomers of the ligand are superimposed at their Cα-atoms. The amino acid side chains and the ligand are shown as sticks, whereas the β-hairpin in EL2 is shown in cartoon. The ligand is colored by atom type, whereas the protein is colored according to the bound isomer, i.e. green for 5S8R, yellow for 5R8S, violet for 5R8R, and pink for 5S8S.
Figure S9 (related to Figure 8). Comparisons between the binding modes of the four isomers of 13-cis-5,8-ERA and 11-cis retinal. Selected details of the interactions between 13-cis-5,8-ERA and T17M (A, D, G, J), P23H (B, E, H, K), and E181K (C, F, I, L) extracted from the average minimized structures are shown. The ligand is colored by atom type, whereas the protein is colored according to the bound isomer, i.e. green for 5S8R, yellow for 5R8S, violet for 5R8R, and pink for 5S8S. The complexes between each of the three OPS mutants and the ligands 13-cis-5,8-ERA and 11-cis retinal (colored blue) are shown superimposed at the Cα-atoms. The amino acid side chains and the ligand are shown as sticks, whereas the β-hairpin in EL2 is shown in cartoon.
Supplemental Information also includes Tables S1-S9 provided as separate excel sheets.
Transparent Methods

In silico experiments

MD simulations of WT and adRP mutants in their OPS and RHO forms

The crystal structures encoded as 3CAP (Park et al., 2008) and 1GZM (Li et al., 2004) were employed as inputs to simulate, respectively, the OPS and RHO states of WT and 33 adRP mutants. The mutants were selected based on: (a) their diversified distribution in the protein portions, (b) the non-conservative nature of the amino acid substitution, and (c) previously reported biochemical properties (references are collected in Briscoe et al., 2004, Krebs et al., 2010, Rakoczy et al., 2011).

The simulated structures of the OPS and RHO states are, respectively, 323 and 326 amino acid long; elimination of the last three amino acids served to reduce the high mobility of H8 in the OPS state. For all mutants but a few exceptions (see below) the native disulphide bridge between C110 and C187 (in EL2) was set.

Energy minimizations and MD simulations were carried out by means of the CHARMM force field (in all-atom mode) (Brooks et al., 2009), using the GBSW implicit membrane/water model (Im et al., 2003). For the 11-cis retinal PSB, we employed the all-atom topologies and parameters introduced in the version c32b2 of the force field. With respect to the physical parameters representing the membrane in the GBSW model, the surface tension coefficient (representing the non-polar solvation energy) was set to 0.03 kcal/(mol Å^2). Membrane thickness (centered at Z = 0) was set to 30.0 Å with a membrane smoothing length of 5.0 Å.

Prior to MD simulations, the system was energy minimized by 500 steps of Adopted Basis Newton-Raphson (ABNR) minimization (Chu et al., 2003). The minimized coordinates were heated to 300 K, as well as to 329 K and 345 K (for melting temperature simulations of the OPS and RHO states, respectively), by randomly assigning velocities from a Gaussian distribution. After heating, the system was allowed to equilibrate for 100 ps. An integration step of 0.002 ps was used. Equilibrium MD simulations at the three different temperatures were carried out for 10 ns. For each mutant characterized by torsion angles in the replaced side chain, a minimum of three rotamers were probed by MD, corresponding to the Dunbrack and Karplus (D&K) (Dunbrack and Karplus, 1993), Ponder and Richards (P&R) (Ponder and Richards, 1987), and Sutcliffe (Sut) (Sutcliffe et al., 1987), rotamer libraries. Additional side chain conformations were probed by assigning the average values of the dihedral a given amino acid assumes in the helices or in the
loops of the OPS and RHO structures. For the substitutions deprived of side chain rotamers (i.e. alanine, glycine, and proline), three replicas were carried out by assigning different random seeds. In addition to native disulphide bridge, for the C110Y, Y178C, and C187Y other disulphide bridges were probed. These bridges involved the C185-C187 pair for C110Y, the C178-C110 or C178-C187 pairs for Y178C, and the C185-C110 pair for C187Y. For the G89D, L125R, A164V, H211P, and H211R mutants, simulations in the presence of the native disulphide bridge and of the non-native C185-C187 bridge were carried out. Given the low resolution of the in vitro data postulating the formation of the non-native bridge for such mutants (Hwa et al., 2001) and to save consistency with all the other cysteine-non involving mutants considered in this study, we decided to consider only the structures holding the native bridge. On average, for each mutant in the two different functional states (OPS and RHO), considering one likely prototropic form of the mutated side chain (when applicable), five MD trajectories per temperature (i.e. 300 K or 345/329 K) were produced and subjected to PSN analysis (i.e. on average 100 ns per mutant in a given functional state).

The average minimized structures of the selected mutant trajectories at 300 K were used to compute the Vout index concerning retinal, by means of the Wordom software (Seeber et al., 2011). This index, which is the outer van der Waals molecular volume of the retinal in the structure of a given mutant relative to that in the structure of WT RHO, was computed following superimpositions of each mutant on the WT. Superimpositions concerned the retinal and the backbone atoms of 142 amino acid residues in the extracellular half of the receptor.

The same MD simulation protocol used for WT and mutated OPS and RHO was employed for the four isomers (i.e. 5S8R, 5R8S, 5R8R, and 5S8S) of the pharmacological chaperone discovered in this study (i.e. 13-cis-ERA) docked onto the 1GZM structure in place of the retinal. The compound was parametrized according to the CHARMM General Force Field. The WT complexes were mutated to produce the T17M, P23H, and E181K structures used as well as inputs of simulations.

**PSN analysis**

PSN analyses were carried out by means of the Wordom software (Seeber et al., 2011) on the WT and mutated forms of OPS, RHO, and the complexes with 13-cis-5,8-ERA. The PSN implemented in Wordom, based on the approach described in relevant papers by Vishveshwara and co-workers (Vishveshwara et al., 2002, Brinda and Vishveshwara, 2005), is a product of graph theory applied to protein structures. A graph is defined by a set of points (nodes) and connections (edges) between them. In a protein structure graph, each amino acid is represented as a node and these
nodes are connected by edges based on the strength of non-covalent interactions between nodes (Vishveshwara et al., 2009). The strength of interaction between residues i and j ($I_{ij}$) is evaluated as a percentage given by the following equation:

$$I_{ij} = \frac{n_{ij}}{\sqrt{N_i N_j}} \times 100$$

where $I_{ij}$ is the percentage interaction between residues i and j; $n_{ij}$ is the number of atom-atom pairs between residues i and j within a distance cutoff (4.5 Å); $N_i$ and $N_j$ are normalization factors for residue types i and j, which take into account the differences in size of the side chains of the different residue types and their propensity to make the maximum number of contacts with other amino acid residues in protein structures. The normalization factors for the 20 amino acids in the Wordom implementation were taken from the work by Kannan and Vishveshwara (Kannan and Vishveshwara, 1999), whereas the normalization value for retinal, i.e. 170.13, was computed as the average number of contacts made by the molecule in a dataset of 83 crystallographic structures concerning the different photointermediate states of bacteriorhodopsin, bovine RHO, sensory RHO, and squid RHO. The normalization factors of the four isomers of 13-cis-5,8-ERA were computed as the average numbers of contacts made by the molecule in 10000 frames of the MD trajectory of each isomer in complex with WT RHO (i.e. 5S8R = 103.06, 5R8S = 118.67, 5R8R = 130.42, and 5S8S = 123.89).

According to the approach, $I_{ij}$ is calculated for all nodes, excluding $i \pm n$, where n is a given neighbor cutoff, 2 in this case. An interaction strength cutoff $I_{\text{min}}$ is then chosen and any residue pair ij for which $I_{ij} \geq I_{\text{min}}$ is considered to be interacting and hence connected in the protein structure graph (PSG). The residues making four or more edges are referred to as hubs at that particular $I_{\text{min}}$. The four-link cutoff relates to the intrinsic limit in the possible number of non-covalent connections made by an amino acid in protein structures due to steric constraints and it is close to its upper limit. Most amino acid hubs indeed make from 4 to 6 links. Node interconnectivity is finally used to highlight cluster-forming nodes, where a cluster is a set of connected amino acids in a graph. Node clustering procedure is such that nodes are iteratively assigned to a cluster if they could establish a link with at least one node in such cluster. A node not linkable to existing clusters initiates a novel cluster and so on until the node list is exhausted. Cluster size, defined as the number of nodes, varies as a function of the $I_{\text{min}}$, and the size of the largest cluster is used to calculate the $I_{\text{crit}}$ value, which is worth using as an $I_{\text{min}}$ cutoff for the analysis (Brinda and
Vishveshwara, 2005). An analysis of 200 different proteins showed that, irrespective of the protein size or fold, the size of the largest cluster in each of the proteins undergoes a transition at a particular \( I_{\text{min}} \) value. This \( I_{\text{min}} \) value at which the size of the largest cluster decreases dramatically (i.e., the midpoint of the transition) was indeed the \( I_{\text{critical}} \) \( (\text{Brinda and Vishveshwara}, 2005) \). The latter is therefore defined as the \( I_{\text{min}} \) at which the size of the largest cluster is half the size of the largest cluster at \( I_{\text{min}} = 0.0\% \). We set the \( I_{\text{min}} \) equal to the \( I_{\text{critical}} \) approximated to the second decimal place.

To compute the native stable structure network, the frequencies of all hubs and the number of all links in the 300 K network were averaged with the frequencies of the same hubs and the number of links in the corresponding melting temperature network (329 K for OPS and 345 K for RHO). In this respect, the frequency of a hub or link is the number of frames holding the considered hub or link divided by the total number of frames in the trajectory. The PSGs then served to quantify the differences in structure network between WT and mutants through the computational index called \( \text{NP} \) and described in the Result section.

Mutants were grouped into clusters by means of the Partitioning Around Medoids (PAM) algorithm \( (\text{Kaufman and Rousseeuw}, 1987) \) according to their pairwise distances defined in a 3D coordinate system. In this coordinate system, each mutant is indeed described by a vector of three variables: the \( \text{NP} \) scores computed on the OPS and RHO forms of each mutant and the difference between them \( (\Delta \text{NP}) \). Prior to cluster analysis the coordinates of each mutant were centered by subtracting the variable mean value. The number of clusters \( k \), in which the dataset had to be partitioned, was set equal to 4 according to the average Silhouette Width Index (SW) \( (\text{Rousseeuw}, 1987) \), which is a measure of how well individual elements fit into the assigned cluster. To further corroborate the results of cluster analysis, other clustering algorithms were tested, e.g. the hierarchical clustering and k-means. A partial list of these tests includes: different ways to center and scale the 3D matrix providing the distances between mutant pairs, six different linkage criteria for hierarchical agglomerative clustering and four different ways to calculate the difference between OPS and RHO NPs. The combination of all these variables lead to more than 100 different clustering conditions, which generated the same mutant partitions when the highest SWi value was used to select the number of clusters.
Virtual screening of compounds

The over 13 million compound library resulting from the merger of the over 17 million compounds in the Drug-like, Lead-like, NCI, and NCIdiv sets from the ZINC database (http://zinc.docking.org/) (Irwin and Shoichet, 2005, Irwin et al., 2012) were divided in three sets according to the compound net charge at physiological pH. For the present study, we focused on the set of negatively charged compounds, whose chemical redundancy was minimized leading to a set of 225,487 compounds. Two different sets of negatively charged compounds (104,883 and 7,597) characterized by a predicted logP (i.e. xlogP, taken from the ZINC database (http://zinc.docking.org/)) between 5 and 7 were prepared as well. The compound libraries were virtually screened onto the retinal-binding sites of the crystal structures of WT OPS (PDB code: 3CAP), octylglucoside (OG)-stabilized OPS (4J4Q), RHO (1GZM and 1U19 with and without structural water molecules). Virtual screening was carried out by the means of the Glide software (Friesner et al., 2004, Friesner et al., 2006). Filtering of the top 1000 hits from each docking run relied on the docking score as well as on size/shape descriptors of the retinal mimicry potential of each compound. The index, Vdif (De Benedetti and Fanelli, 2010, Fanelli and De Benedetti, 2011), was computed by means of the Wordom software (Seeber et al., 2011) according to the following formula: $V_{in} - V_{out} / V_{sup}$, where $V_{in}$ and $V_{out}$ are, respectively, the intersection and the outer van der Waals volumes of each ligand in the predicted docking mode with respect to the van der Waals volume of a reference supermolecule ($V_{sup}$). In the present study, the supermolecule was 11-cis retinal from the target crystal structure. For the docking into the OPS and OG-stabilized OPS structures, the retinal coordinates extracted from 1GZM following Cα-atom superimposition of the two proteins were employed as a supermolecule. Moreover, for these two target structures, the detergent OG was additionally employed as a supermolecule for the computation of the Vdif index.

Hit compounds in common between the different runs received priority for final selection.

A first selection of 20 compounds (Table S7) almost all characterized by xlogP ≥ 5 out of a first list of 254 hits checked for commercial availability, was sent to in vitro testing.

In vitro experiments

cDNA constructs and site directed mutagenesis

The cDNA for human RHO (Angeletti et al., 2003) was cloned into the mammalian expression plasmid pRc/CMV using the HindIII/XbaI restriction sites (pRc/CMV-RHO). Site directed
Mutagenesis was performed with a QuikChange® Site-Directed Mutagenesis Kit and primers containing the desired base change. All mutagenized cDNAs were checked by sequencing. Below is the list of mutagenized amino acids and the corresponding oligonucleotides, used for site directed mutagenesis, in which the mutagenized base is indicated as bold underlined letter:

| Amino Acid | Oligonucleotide |
|------------|-----------------|
| T4K        | GAATGGCAAAAGAAGGCCCTAAC |
| T17M       | CAATGCAGTGGGTGTTGTA |
| P23H       | CAGCCACTTCGAGTACCC |
| Q28H       | GAGTACCACATTACTACCTGG |
| M44T       | GCCGCTACAAGTTTCTGCTG |
| F45L       | CTACATGGTCTGCTGATCG |
| L46R       | ATACATGTTCTGGCTGATCG |
| G51A       | CTTGGCTGCCTCCCATC |
| P53R       | GGGCTTCGACATCAACTTC |
| T58R       | CAACTTCCTCCTGGCTCTACGTC |
| V87D       | TTCATGGACCTAGGTTGGCTTC |
| G89D       | GTCTACAGTTGGCTCTACGAC |
| G106R      | CTTCGTCTCCGGCCACAG |
| C110Y      | CACAGGATACAATTTGGAGGGC |
| G114D      | CAAATGGAGGACTTCTTGCC |
| L125R      | ATTCGCCGTTGGTCTCCTTG |
| R135W      | CCATCGAGTGGTGACGTG |
| V137M      | GCCTACATGGGTGTTGTA |
| A164V      | GTACATGGTCTGGCTGCG |
| C167R      | GCCTGGCGCCGC CGCCGCACC |
| P171Q      | CCGACCCCCA AACTC GCCGGC |
| Y178C      | GGTCAGG GCTCATCCCCAG |
| P180A      | CAGGTACATCGCCAGG GGCCTG |
| E181K      | GTACATCCCAAGGGCCTGAG |
| S186P      | CCTGCA GTGCGCCGCTGCTG |
| C187Y      | CAGTGCTCGTATGGGAATCGAC |
| G188R      | GCTCGTGTG AATCGACTAC |
D190G  GGAATCGGCTACTACACGCTC  
D190Y  TGTGGAATCTACTACACGCT  
H211P  GTTCGTGGTCCCTTCACCATCC  
H211R  GTTCGTGGTCCCTTCACCATCC  
C222R  CATCTTTTTCAGGTATGGGCAGCTC  
P267L  CTGGGTGCTCTACGCCAGG

**Cell culture and transfection of COS-7 cells**

Twenty-four hours prior transfection COS-7 cells were seeded onto 12 mm gelatin coated glass coverslips at a density of 2x10^4 cells per slide. Cells were transfected with WT and mutant pRc/CMV-RHO constructs by calcium phosphate transfection as described previously (Graham and van der Eb, 1973). Briefly, 4 hours prior transfection cells were fed with 270 µl of fresh medium. Plasmid DNA (1 µg) was resuspended in 13.5 µl sterile water and 1.5 µl 2.5 M CaCl_2 was added (final concentration: 250 mM). Subsequently the CaCl_2-DNA mix was added drop wise and under permanent mixing to 15 µl HEPES-buffered saline (HBS: 50 mM HEPES, 1.5 mM Na_2HPO_4, 280 mM NaCl, pH 7.11). After incubation for twenty minutes at room temperature the DNA-CaCl_2-HBS mix was overlaid on cells. Twenty-four hours after transfection cells were washed twice with phosphate buffered saline (PBS) and fresh complete DMEM with or without 10 µM 9-cis retinal, all-trans retinal or new compounds was added in the dark. For calculation of EC50 9-cis retinal and the 13-cis-5,8-ERA compound were added at different concentrations from 0 to 50 µM. No significant differences in transfection efficiencies were observed with different constructs (WT or mutants) and transfected cells expressed OPS protein of expected molecular weight as assessed by western blotting (Figure S3A). For each experiment at least three slides were analyzed for ER- and plasma membrane-localization in the presence and absence of retinal.

**Immunohistochemistry**

Forty-eight hours after transfection cells were fixed with 2 % paraformaldehyde in PBS for ten minutes. For co-localization analysis fixed cells were permeabilized and blocked in PBS with 3% BSA and 0.1 % TritonX-100 for 1 hour at room temperature (3% BSA and 0.1 % TritonX-100 for 30 min followed by 3% BSA for additional 30 min for anti-PERK), washed five times with PBS and incubated with the monoclonal mouse anti-OPS antibody 1D4 (epitope at the C-terminal of OPS) together with the polyclonal rabbit anti-calnexin antibody CLNX or rabbit anti-PERK antibody for 1
hour at room temperature. To analyze the membrane localization of OPS/RHO, fixed cells were blocked in PBS with 3% BSA without detergent to avoid permeabilization of the cell membrane and incubated with the primary mouse anti-OPS antibody RetP1 (epitope at the N-terminal of OPS). To confirm that the RetP1 antibody was able to detect wild type as well as mutated OPS/RHO we evaluated RetP1 staining after permeabilization for those mutants that failed to show a signal in non-permeabilized cells (Figure S6). As secondary antibodies Alexa Fluor 568 goat anti-mouse and Oregon-Green 488 goat anti-rabbit antibodies were used and 0.1 µg/ml DAPI for nuclear staining. Slides were mounted with Mowiol 4-88 and analyzed with a Zeiss Axioskop 40 FL fluorescence microscope equipped with a digital camera, AxioCam, and AxioVision Rel version 4.8 software for image processing. Confocal analysis was performed using a Leica laser confocal microscope system.

**Digital Image analysis**

Image processing, including measurements of the Pearson Correlation Coefficient (PCC) and cell-counting was conducted using the open source ImageJ v1.48 software. Co-localization of the 1D4 and CLNX immunofluorescence was evaluated in mononucleated or binucleated cells, without any bias, by calculating the PCC which determines the relative fluorescence intensities of the green Oregon-Green 488 (labeling CLNX) and red Alexa Fluor 568 (labeling 1D4) in the same groups of pixels in a region of interest (ROI) (Dunn et al., 2011). Indeed, consistency was found when PCC values were computed in an unbiased manner, or on mononucleated, or on multinucleated cells (Table S9). The PCC-formula for an image consisting of a red and green channel is given below:

\[
PCC = \frac{\sum_i (R_i - \bar{R}) \times (G_i - \bar{G})}{\sqrt{(R_i - \bar{R})^2 \times (G_i - \bar{G})^2}}
\]

\(R_i\) and \(G_i\) are the intensity values of pixels and \(\bar{R}\) and \(\bar{G}\) the mean intensities of the red and green channels across the entire ROI respectively.

The channels of single RGB images were split into grayscale pictures and the red and green channels used for analysis. An ROI in the red channel was created by free hand drawing around the OPS/RHO fluorescence in single cells and used for calculating PCC (see Ref. (Dunn et al., 2011) for details; Figure S3B). PCC values can range from 1 to -1. Whereas a value of 1 represents perfect correlation, value -1 represents perfect but inverted correlation and values near zero represent distributions of fluorescent signals that are uncorrelated with one another (Dunn et al., 2011).
The percentage of cells expressing WT and mutant OPS/RHO was determined by counting the number of DAPI-stained cells and the number of 1D4+ cells. To evaluate the percentage of cells with WT and mutant OPS/RHO on the cell surface the same procedure was performed with images taken from cells immunostained with RetP1 without membrane permeabilization. For each experiment, the percentage of RetP1+ divided by the percentage of 1D4+ cells (RetP1/1D4) was calculated. The mean PCC- and RetP1/1D4-values of at least three independent experiments were used for statistical analysis by Student's unpaired t test. All data are presented as mean values ± standard errors of the means (SEMs).

For PCC computation on the 33 adRP mutants in their OPS and RHO forms, the number of analyzed cells was on average 45 ± 14 per mutant form.

For PCC-based EC50 calculations, 30 cells were analyzed for each concentration (nine) of 9-cis retinal and 13-cis-5,8-ERA on three mutants (T17M, P23H, and E181K).

**Preparation of opsin membranes**

All experimental procedures were carried out in a darkroom under dim red light (>670 nm). Bovine rod outer segments (ROS) were prepared as described elsewhere (Baker et al., 2015, Cogan et al., 1976, Gulati et al., 2017, Okada et al., 1994, Papermaster, 1982). ROS were washed with isotonic and hypotonic buffer to remove both soluble and membrane associated ROS proteins (Baker et al., 2015). Purified ROS membranes (19.3 mg ml⁻¹ Rh) were bleached with a 100 W white light for 30 min in the presence of 20 mM hydroxylamine. Bleached ROS/opsin membranes then were washed six times each with 35 ml of buffer containing 67 mM potassium phosphate, pH 7.0, 1 mM magnesium acetate, 0.1 mM EDTA and 1 mM dithiothreitol to dispose of excess hydroxylamine.

**5,8-Epoxy-13-cis retinoic acid binding assays with opsin**

Opsin membranes at the final concentration of 3.4 µM were solubilized in buffer containing 20 mM Bis-Tris-Propane, pH 6.9, 100 mM NaCl and 0.1% n-dodecyl β-D-maltoside (DDM). Absorption spectra of solubilized opsin membranes were measured with a Cary 50 UV-Vis spectrophotometer maintained at 20 °C (TC 125 temperature controller, Quantum Northwest Inc., USA). 13-cis-5,8-ERA was added to achieve a final concentration of 37.5 µM in these membranes and incubated for 15 min at 20 °C before the addition of 9-cis retinal to a final concentration of 7.5 µM. Binding experiments were carried out for 25 min and absorption spectra were measured every 1 min. The
time-dependent absorption spectra were fitted with an exponential function wherein the slope of the fitting curve corresponded to the apparent half-life of iso-rhodopsin regeneration.

**Tryptophan fluorescence spectroscopy**

To confirm the binding of 13-cis-5,8-ERA in the retinal-binding pocket of OPS, quenching of opsin tryptophan residues was monitored before and after treatment with increasing concentrations of either 13-cis-5,8-ERA acid or 9-cis retinal (Cogan et al., 1976, Golczak et al., 2008). Fluorescence was measured at 20 °C with an L55 luminescence spectrophotometer (PerkinElmer Life Sciences, USA) operating at excitation wavelength of 295 nm and an emission wavelength range of 300 and 500 nm (Alexander et al., 2017). The emission slit was set between 5 and 10 nm with an acquisition speed of 300 nm s⁻¹. Opsin membranes at the final concentration of 3.4 nM were solubilized in buffer containing 20 mM Bis-Tris-Propane, pH 6.9, 100 mM NaCl and 0.1% DDM. Change in fluorescence (ΔF/F₀; where ΔF is the difference between the tryptophan fluorescence spectrum before (F₀) and after the addition of ligand at specified concentrations) were plotted as a function of the ligand concentration. Binding experiments with 13-cis-5,8-ERA and 9-cis retinal were carried out at a concentration range of 0-102 nM and 0-1470 nM, respectively. The ligands were incubated for 2 min before the measurements. The raw tryptophan fluorescence spectra were corrected for background and the inner filter effect caused by the self-absorption of excitation and emission light. The binding curves were fitted with the Hill equation to obtain EC₅₀ values.

**Supplemental References**

Alexander, N. S., Katayama, K., Sun, W. Y., Salom, D., Gulati, S., Zhang, J. Y., Mogi, M., Palczewski, K. and Jastrzebska, B. (2017). Complex binding pathways determine the regeneration of mammalian green cone opsin with a locked retinal analogue. Journal of Biological Chemistry 292, 10983-10997.

Angeletti, B., Loster, J., Auricchio, A., Gekeler, F., Shinoda, K., Ballabio, A., Graw, J. and Marigo, V. (2003). An in vivo doxycycline-controlled expression system for functional studies of the retina. Invest Ophthalmol Vis Sci 44, 755-60.

Baker, B. Y., Gulati, S., Shi, W. X., Wang, B. L., Stewart, P. L. and Palczewski, K. (2015). Crystallization of Proteins from Crude Bovine Rod Outer Segments. Membrane Proteins - Engineering, Purification and Crystallization 557, 439-458.
Brinda, K. V. and Vishveshwara, S. (2005). A network representation of protein structures: implications for protein stability. Biophys J 89, 4159-70.

Briscoe, A. D., Gaur, C. and Kumar, S. (2004). The spectrum of human rhodopsin disease mutations through the lens of interspecific variation. Gene 332, 107-18.

Brooks, B. R., Brooks, C. L., 3rd, Mackerell, A. D., Jr., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, R. W., Post, C. B., Pu, J. Z., Schaefer, M., Tidor, B., Venable, R. M., Woodcock, H. L., Wu, X., Yang, W., York, D. M. and Karplus, M. (2009). CHARMM: the biomolecular simulation program. J Comput Chem 30, 1545-614.

Chu, J.-W., Trout, B. L. and Brooks, B. R. (2003). A super-linear minimization scheme for the nudged elastic band method. J. Chem. Phys. 119, 12708-12717.

Cogan, U., Kopelman, M., Mokady, S. and Shinitzky, M. (1976). Binding Affinities of Retinol and Related Compounds to Retinol Binding-Proteins. European Journal of Biochemistry 65, 71-78.

De Benedetti, P. G. and Fanelli, F. (2010). Computational quantum chemistry and adaptive ligand modeling in mechanistic QSAR. Drug Discov Today 15, 859-66.

Dunbrack, R. L., Jr. and Karplus, M. (1993). Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J Mol Biol 230, 543-74.

Dunn, K. W., Kamocka, M. M. and McDonald, J. H. (2011). A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol 300, C723-42.

Fanelli, F. and De Benedetti, P. G. (2011). Update 1 of: Computational Modeling Approaches to Structure-Function Analysis of G Protein-Coupled Receptors. Chem Rev 111, PR438-535.

Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P. and Shenkin, P. S. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739-49.

Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C. and Mainz, D. T. (2006). Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49, 6177-96.
Golczak, M., Maeda, A., Bereta, G., Maeda, T., Kiser, P. D., Hunzelmann, S., VonLintig, J., Blaner, W. S. andPalczewski, K. (2008). Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina. Journal of Biological Chemistry 283, 9543-9554.

Graham, F. L. andVan Der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-67.

Gulati, S., Jastrzebska, B., Banerjee, S., Placeres, A. L., Miszta, P., Gao, S. Q., Gunderson, K., Tochtrop, G. P., Filipek, S., Katayama, K., Kiser, P. D., Mogi, M., Stewart, P. L. andPalczewski, K. (2017). Photocyclic behavior of rhodopsin induced by an atypical isomerization mechanism. Proceedings of the National Academy of Sciences of the United States of America 114, E2608-E2615.

Hwa, J., Klein-Seetharaman, J. andKhorana, H. G. (2001). Structure and function in rhodopsin: Mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants. Proc Natl Acad Sci U S A 98, 4872-6.

Im, W., Feig, M. andBrooks, C. L., 3rd (2003). An implicit membrane generalized born theory for the study of structure, stability, and interactions of membrane proteins. Biophys. J. 85, 2900-18.

Irwin, J. J. andShoichet, B. K. (2005). ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model 45, 177-82.

Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S. andColeman, R. G. (2012). ZINC: A Free Tool to Discover Chemistry for Biology. Journal of Chemical Information and Modeling 52, 1757-1768.

Kannan, N. andVishveshwara, S. (1999). Identification of side-chain clusters in protein structures by a graph spectral method. J Mol Biol 292, 441-64.

Kaufman, L. andRousseeuw, P. J. (1987) Clustering by means of Medoids. IN Y. DODGE, N.-H. (Ed.) Statistical Data Analysis Based on the L1–Norm and Related Methods. (North-Holland), 405-416.

Krebs, M. P., Holden, D. C., Joshi, P., Clark, C. L., 3rd, Lee, A. H. andKaushal, S. (2010). Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. J Mol Biol 395, 1063-78.

Li, J., Edwards, P. C., Burghammer, M., Villa, C. andSchertler, G. F. (2004). Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343, 1409-38.
Okada, T., Matsuda, T., Kandori, H., Fukada, Y., Yoshizawa, T. and Shichida, Y. (1994). Circular-Dichroism of Metaiodopsin-li and Its Binding to Transducin - a Comparative-Study between Meta-li Intermediates of Iodopsin and Rhodopsin. Biochemistry 33, 4940-4946.

Papermaster, D. S. (1982). Preparation of Retinal Rod Outer Segments. Methods in Enzymology 81, 48-52.

Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H. W. and Ernst, O. P. (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454, 183-7.

Ponder, J. W. and Richards, F. M. (1987). Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. J Mol Biol 193, 775-91.

Rakoczy, E. P., Kiel, C., Mckeone, R., Stricher, F. and Serrano, L. (2011). Analysis of Disease-Linked Rhodopsin Mutations Based on Structure, Function, and Protein Stability Calculations. J Mol Biol 405, 584–606.

Rousseeuw, P. J. (1987). Silhouettes: a Graphical Aid to the Interpretation and Validation of Cluster Analysis. Computational and Applied Mathematics 20, 50-65.

Seeber, M., Felline, A., Raimondi, F., Muff, S., Friedman, R., Rao, F., Caflisch, A. and Fanelli, F. (2011). Wordom: A user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. J Comput Chem 32, 1183-94.

Sutcliffe, M. J., Hayes, F. R. and Blundell, T. L. (1987). Knowledge based modelling of homologous proteins, Part II: Rules for the conformations of substituted sidechains. Protein Eng 1, 385-92.

Vishveshwara, S., Brinda, K. V. and Kannan, N. (2002). Protein structure: insights from graph theory. J. Theor. Comput. Chem. 1, 187-211.

Vishveshwara, S., Ghosh, A. and Hansia, P. (2009). Intra and inter-molecular communications through protein structure network. Curr Protein Pept Sci 10, 146-60.